Valeant gets aggressive in Cephalon bid, Demands Decision by 12 May
This article was originally published in Scrip
Executive Summary
Just as many predicted, Canadian drug maker Valeant has moved quickly to woo Cephalon shareholders in its attempted $5.7 billion hostile bid for Cephalon.